Xu H; Kamei C; Gökbuget D; Du J; Barrero M; Wang L; Iwamoto Y; Soriano JM; Godding K; Wang B; Kwek SS; Nistor GI; Keirstead HS; Fong L; Kaneko S; Gaensler KML; Blelloch R · 2026 · Cell stem cell
Paper
Autologous-derived dendritic cells (DCs) are a promising source for cell-based cancer vaccines. However, their therapeutic potential is challenged by the number and quality produced and the diversity of antigens presented. To address these limitations, we present an approach that involves differentiating universal MHC-deficient human-induced pluripotent stem cells (hiPSCs) into CCR7 + migratory DCs. These DCs are subsequently "dressed" with the full repertoire of MHC-antigen complexes derived from tumor cell membranes, transforming an allogeneic substrate into a personalized cancer vaccine product. The resulting "TumorDressed" DCs effectively activate T cells against tumor antigens. Their function is diminished when CD80/86 is deleted but significantly enhanced by the loss of PD-L1/2. PD-L1/2-null TumorDressed DCs demonstrate robust priming of anti-tumor T cell-mediated cytotoxicity both in vitro and in vivo, including against primary hematologic and solid tumors with matching patient T cells. These findings provide proof of concept for a universal, scalable, adaptable, and off-the-shelf DC cancer vaccine platform.
Analysis
Preparing paper insights from the available abstract and paper details.
Discovery
Dinghai Zheng; Justin Hong; Jun Wang; Adrien Villain; Mickaël Costallat; Fernando Ulloa Montoya; Vikram Agarwal
Almohanad A. Alkayyal
Kali SK; Ramesh RPG; Alam A; Fernandez-Cabezudo MJ; Al-Awadhi AM; Kishore U; Al-Ramadi BK
Bian MY; Stevens R; Mangla A; Mitra D; Zaorsky NG; Bordeaux JS; Rothermel LD
Caldarelli M; Rio P; Renna C; Marrone A; Guazzarotti G; Gasbarrini A; Gambassi G; Cianci R
Matsumoto M; Takayama R; Matsuguchi C; Shimada H; Izumi T; Kato N; Matsuo-Tani A; Nakamura H; Hiu T; Matsuo T; Mukai H; Kawakami S
Source record